Skip to main content
Equibles
MTNB logo

MTNB · Matinas BioPharma Holdings, Inc.

Track MTNB — free

Use MTNB with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about MTNB

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.23 +0.00 (+0.43%) At close · Aug 14
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We do not believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital requirements for a period of at least the next twelve months from the filing date of this Quarterly Report. As a result, substantial doubt exists about our ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$3.44M
Shares
14.69M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.23 Open$0.24 Day$0.22–0.25 52W close$0.23–2.36 Avg vol 30d10.8M Short int840K · 5.7% float · 1.0d Short vol44% Last earningsAug 14, 2024 DataSep 2024–Aug 2026 Filing10-Q · Aug 13

Raw chart and full-history price indicators begin at the captured split on Sep 3, 2024; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Bearish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −65%
below
Price vs 50-day avg −53%
below
RSI (14) 32
neutral
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −32%
trailing
6-month return −62%
trailing
YTD return −60%
this year
Relative strength −75%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-11% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.72% of float · ▲ +77.3% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
25 holders — mid 3-yr range
Squeeze score 52
elevated · 0–100
Fundamentals
Fair
Revenue growth −20%
Y/Y
EPS growth +60%
Y/Y
Free cash flow $-7.2M
Balance sheet $4.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 124%
annualized · 1-yr
Max drawdown −90%
past year
ATR 23.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
3 · 2 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−65% Bearish
Price vs 50-day avg
−53% Bearish
RSI (14)
32 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-11% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.72% of float · ▲ +77.3% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
25 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $2
vs 200-day avg -65% vs 50-day avg -53%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MTNB
Matinas BioPharma Holdings, Inc.
this stock
$3.44M -60.1% -20.0% — 5.7%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
25
% held
2.2%
Net QoQ
-29.3K sh
Top holder
RENAISSANCE TECHNOLOGIES…
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Rising
Shares short
840.0K
Days to cover
1.0d
Change
+366.3K sh
View
Short Volume
Short vol %
44%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
119.0K
Value
$57.1K
As of
Jul 14, 2026
View
Off-Exchange
Off-exchange %
61.8%
Week of
Jul 6, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.1M
Net income (FY)
$-10.3M
EPS diluted
$-2.00
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 13, 2026
This year
8
View
Exempt Offerings
Offering
$3.3M
Filed
Feb 19, 2025
View
Earnings & Events
Earnings Calls
Last call
Aug 14, 2024
View

Performance

Raw-price comparisons begin at the captured split on Sep 3, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
MTNB -17.3% -32.0% -61.6% -20.4% -60.1%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY -17.7% -36.4% -75.4% -24.3% -73.9%
Key facts CIK 1582554 CUSIP 576810303 13F (30d) 24 filings 24 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)